<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04401137</url>
  </required_header>
  <id_info>
    <org_study_id>QDX001</org_study_id>
    <nct_id>NCT04401137</nct_id>
  </id_info>
  <brief_title>The Evaluation of Pharmacokinetic/Pharmacodynamic Characteristics and Safety of QDX in Healthy Korean Male Subjects</brief_title>
  <official_title>A Single Center, Randomized, Double Blind, Placebo Controlled, Dose Escalation Clinical Trial to Evaluate Pharmacokinetic/Pharmacodynamic Characteristics and Safety of QDX After Single Oral Administration in Healthy Korean Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>SK Chemicals Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>SK Chemicals Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate pharmacokinetic/pharmacodynamic characteristics and safety of QDX after single
      oral administration in healthy Korean male subjects
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 1, 2020</start_date>
  <completion_date type="Anticipated">November 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Capsaicin-Induced Dermal Blood Flow (DBF)</measure>
    <time_frame>Pre-dose(-2 hour), 2 hour, 4 hour, 8 hour, 24 hour post-dosing on Day1</time_frame>
    <description>Change from Baseline in Dermal Blood Flow Induced by QDX Compared to Placebo</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration-time Curve From Time Zero to the Time of Last Quantifiable Concentration (AUC[0-T])</measure>
    <time_frame>Pre-dose(-2 hour), 2 hour, 4 hour, 8 hour, 12hour, 24 hour post-dosing on Day1</time_frame>
    <description>Area under the plasma concentration-time curve from time zero to the time of the last quantifiable concentration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration-time Curve From Time Zero to the Time of Last Quantifiable Plasma Concentration (AUClast)</measure>
    <time_frame>Pre-dose(-2 hour), 2 hour, 4 hour, 8 hour, 12hour, 24 hour post-dosing on Day1</time_frame>
    <description>Area under the plasma concentration-time curve from time zero to the last quantifiable concentration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax)</measure>
    <time_frame>Pre-dose(-2 hour), 2 hour, 4 hour, 8 hour, 12hour, 24 hour post-dosing on Day1</time_frame>
    <description>Maximum observed plasma concentration following drug administration from the raw plasma concentration-time data.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Reach Maximum Plasma Concentration (Tmax)</measure>
    <time_frame>Pre-dose(-2 hour), 2 hour, 4 hour, 8 hour, 12hour, 24 hour post-dosing on Day1</time_frame>
    <description>Tmax was defined as the time required to reach maximum observed plasma concentration.</description>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Migraine</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>QDX 25</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>QDX 50</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>QDX 100</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>QDX 200</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Topiramate</intervention_name>
    <description>Topiramate</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>QDX 100</arm_group_label>
    <arm_group_label>QDX 200</arm_group_label>
    <arm_group_label>QDX 25</arm_group_label>
    <arm_group_label>QDX 50</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants who have fully understood this clinical trial via detailed explanation,
             are willing to voluntarily participate in this study, and agree to give written
             informed consent which is confirmed from IRB.

          -  Healthy male participants aged between 19 and 45 years at screening

          -  Those whose body weight is over 50kg, and BMI is between 18.0 and 27.0

          -  Participants who have demonstrated at least a 100 percent (%) increase in dermal blood
             flow in 30 minutes after capsaicin challenge as part of the screening procedures.

        Exclusion Criteria:

          -  Those who have a clinically significant disease of liver, kidney, digestive,
             respiratory, endocrine, neurologic, blood/tumor, cardiovascular system, or history of
             those diseases

          -  Those who have a history of hypersensitivity or clinically significant
             hypersensitivity reactions to drugs (containing Topiramate etc.)

          -  Those who have a hereditary galactose intolerance, lapp lactase deficiency or
             glucose-galactose malabsorption syndrome

          -  Those who have irritating skin, wounds, eczema, and wounds on the area where capsaicin
             is applied
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sangkeun Choi</last_name>
    <phone>82 02 2008 1926</phone>
    <email>okskchoi@sk.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Seoul National University Hospital, Dept. of Clinical Pharmacology</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <contact>
      <last_name>In-Jin Jang, MD,PhD</last_name>
      <phone>82-2-2072-1666</phone>
    </contact>
    <investigator>
      <last_name>In-Jin Jang, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 14, 2020</study_first_submitted>
  <study_first_submitted_qc>May 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 26, 2020</study_first_posted>
  <last_update_submitted>May 19, 2020</last_update_submitted>
  <last_update_submitted_qc>May 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 26, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Topiramate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

